TEVA PHARMACEUTICAL INDUSTRIES LTD Form 6-K March 20, 2008

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Private Issuer

Pursuant to Rule 13a 16 or 15d 16 under the Securities Exchange Act of 1934

For the month of March 2008

Commission File Number ______0-16174

__1__

Teva Pharmaceutical Industries Limited		
(Translation of registrant's name into English)		
5 Basel Street, P.O. Box 3190		
Petach Tikva 49131 Israel		
(Address of principal executive offices)		
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F		
Form 20-F Form 40-F		
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule		
101(b)(1):		
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):		
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also hereby		
furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934		
Yes NoX		
If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g(3)-2(b):		
82		

Edgar Filing: TEVA PHARMACEUTICAL INDUSTRIES LTD - Form 6-K		
Teva Pharmaceutical Industries Ltd.	Web Site: www.tevapharm	.com
		For Immediate Release
	e Lehman Brothers 11th Annual Global I wen and Company 28th Annual Healthca	
webcast at the Lehman Brothers 11th 28th Annual Healthcare Conference	- Teva Pharmaceutical Industries Ltd. (Nasc Annual Global Healthcare Conference in M in Boston. Dan Suesskind, Chief Financial at Cowen and Company on Wednesday, Ma	Miami and at the Cowen & Company Officer, will present at Lehman
What: Teva Presentation at the Lehr Cowen and Company 28th Annual H	nan Brothers 11th Annual Global Healthcar ealthcare Conference in Boston	e Conference in Miami and at the

Who: Dan Suesskind, Chief Financial Officer

When: Tuesday, March 18, 2008 @ 2:30 p.m. ET, and Wednesday, March 19, 2008 @ 8:45 a.m. ET

Where: http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=TEVA&item_id=1780900

or

http://cc.talkpoint.com/LEHM002/031808a jw/default.asp?entity=TevaPharmaceutical

How: Live over the Internet -- Simply log on to the Web at the address above and register for the event (approx. 10 minutes before). An archive of the webcast will be available on the site.

About Teva

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 20 pharmaceutical companies in the world and is the leading generic pharmaceutical company. The company develops, manufactures and markets generic and innovative pharmaceuticals and active pharmaceutical ingredients. Over 80 percent of Teva's sales are in North America and Western Europe.

__2__

Teva Pharmaceutical Industries Ltd. Edgar Filing: TEVA PHARMACEUTICAL INDUSTRIES LTD - Form 6-K Web Site: www.tevapharm.com

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

TEVA PHARMACEUTICAL INDUSTRIES LIMITED

(Registrant)

By: /s/ Dan Suesskind

Name: Dan Suesskind

Title: Chief Financial Officer

Date: March 17, 2008

__3__